Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining popularity in the management of diabetes in solid organ transplant (SOT) recipients. There are no studies available comparing the two GLP-1RAs dulaglutide and liraglutide in SOT. We performed a retrospective chart review to assess the safety and effectiveness of these agents in adult SOT with diabetes at 6, 12 and 24 months. There were 63 and 25 recipients on dulaglutide and liraglutide, respectively. There was a sustained reduction in primary endpoints of weight, BMI and insulin requirement with dulaglutide when compared to liraglutide. Decrease in weight was 2%, 4% and 5.2% with dulaglutide and 0.09%, 0.87% and 0.89% with liraglutide at 6, 12 and 24 months respectively. BMI reduction followed the same trend in the two groups. The percentage reduction for insulin was 26% with dulaglutide and 3.6% with liraglutide. There was a 10% reduction in creatinine and a 15% increase in estimated glomerular filtration rate (eGFR) at the end of 24 months with dulaglutide. However, there was an increase in creatinine by 7% and an 8% decrease in eGFR at the end of 24 months with liraglutide.

中文翻译：

---

胰高血糖素样肽 1 受体激动剂杜拉鲁肽和利拉鲁肽治疗实体器官移植中糖尿病的比较：一项回顾性研究。

胰高血糖素样肽 1 受体激动剂 (GLP-1RA) 在实体器官移植 (SOT) 受者的糖尿病治疗中越来越受欢迎。目前尚无研究比较两种 GLP-1RAs 度拉鲁肽和利拉鲁肽在 SOT 中的作用。我们进行了回顾性图表审查，以评估这些药物在 6、12 和 24 个月时治疗成人糖尿病 SOT 的安全性和有效性。分别有 63 名和 25 名接受度拉鲁肽和利拉鲁肽的接受者。与利拉鲁肽相比，度拉鲁肽的体重、BMI 和胰岛素需求等主要终点持续降低。6、12 和 24 个月时，度拉鲁肽体重减轻了 2%、4% 和 5.2%，利拉鲁肽体重减轻了 0.09%、0.87% 和 0.89%。两组的体重指数下降趋势相同。度拉鲁肽的胰岛素用量减少百分比为 26%，利拉鲁肽的胰岛素用量减少百分比为 3.6%。使用度拉鲁肽治疗 24 个月后，肌酐降低了 10%，估计肾小球滤过率 (eGFR) 增加了 15%。然而，利拉鲁肽治疗 24 个月后，肌酐增加了 7%，eGFR 降低了 8%。